A recent study by Charles River Associates reveals inequities in access to treatment for multiple sclerosis (MS) across Europe. A summary of key findings, with a link to the full report, can be found at the link below.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...